David Murdoch is Vice President of Corporate Communications for Lyndra Therapeutics, a company pioneering long-acting oral therapies that could make taking daily pills a thing of the past. In this role he’s responsible for leading the company’s internal and external communications, with a primary goal of educating stakeholders on Lyndra’s novel Lynx™ drug delivery platform, which is expected to be commercially available in the next 2-3 years.
Prior to joining Lyndra earlier in 2022, Dave led US Rare Disease Communications for Takeda Pharmaceuticals, supporting the company’s rare bleeding disorders and lysosomal storage disorder commercial businesses. His nearly twenty-year career in healthcare communications includes leadership roles at Sanofi Genzyme, Novartis and Millennium Pharmaceuticals, and he previously worked as a writer and editor for Inc. magazine and Standard & Poor’s.
Dave is a graduate of Boston University’s College of Communication, and he and his family make their home in the Portland, Maine area.